Comparison of crystalline methamphetamine (“ice”) users and other patients with toxicology‐related problems presenting to a hospital emergency department

Dargan, Paul I.

doi:10.5694/j.1326-5377.2008.tb01996.x

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past two decades, numerous studies, conducted in Australia, Canada, and the United States of America (USA), have described the prevalence of amphetamine‐type stimulant use among patients presenting to the ED (Bunting et al, 2007; Cloutier et al, 2013; Dargan & Wood, 2008; Gray et al, 2007; Mehrjerdi & Noroozi, 2013; Richards et al, 2017). A systematic review and meta‐analysis of methamphetamine use among ED presentations reported a total pooled prevalence of 11.3% (Sibanda et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Amphetamine‐type stimulant use among patients admitted to the emergency department behavioural assessment unit: Screening and referral outcomes

Gerdtz

Yap

Daniel

et al. 2020

Int J Mental Health Nurs

View full text Add to dashboard Cite

Amphetamine-type stimulant use, including methamphetamine, amphetamine, and 3,4-methylenedioxymethamphetamine, is associated with a range of behavioural symptoms. Screening for amphetamine-type stimulant use among people presenting to the emergency department with behavioural disturbance and referral to treatment has not been evaluated. The objective of this study was to determine the prevalence of amphetamine-type stimulant use among patients admitted to a behavioural assessment unit and report referral outcomes. A prospective observational design was used. Individuals who tested positive or self-reported amphetamine-type stimulant use were referred to the alcohol and other drug clinician. We measured the prevalence of amphetamine-type stimulant use in saliva and by self-report along with rates of referral. The setting was a behavioural assessment unit located within an Australian emergency department. Admitted adults were enrolled from July to December 2017. Those who tested positive or selfreported amphetamine-type stimulant use were provided with harm reduction advice and offered referral. Four hundred and seventy-two tests were performed. Fifteen were excluded due to invalid results or redundant enrolment. Of the 457 individuals, 59% were male, with a mean age of 35 years (SD 13). Fifty-three (11.6%, 95% CI: 8.9-15.0) tested positive for amphetamine-type stimulants. Of those with a negative test, 44 (9.6%, 95%

show abstract